Shares of Trovagene Inc. (NASDAQ:TROV) were up 3.8% during mid-day trading on Thursday . The company traded as high as $4.80 and last traded at $4.67, with a volume of 238,007 shares trading hands. The stock had previously closed at $4.50.

A number of analysts recently issued reports on TROV shares. Janney Montgomery Scott lowered Trovagene from a “buy” rating to a “neutral” rating in a report on Friday, March 11th. Cantor Fitzgerald reissued a “buy” rating and issued a $10.00 price objective on shares of Trovagene in a research note on Friday, March 11th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $8.00 price objective on shares of Trovagene in a research note on Saturday, March 12th. Maxim Group reissued a “buy” rating on shares of Trovagene in a research note on Saturday, March 12th. Finally, Avondale Partners reissued a “market perform” rating and issued a $6.00 price objective on shares of Trovagene in a research note on Tuesday, March 29th. Six research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $6.96.

The firm’s market cap is $152.59 million. The stock has a 50-day moving average price of $4.82 and a 200 day moving average price of $4.79.

Trovagene (NASDAQ:TROV) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.07. On average, analysts anticipate that Trovagene Inc. will post ($1.30) EPS for the current year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.